Bausch + Lomb Inc. was Bausch Health Companies Inc.’s strongest business in the final year and quarter before the Canadian firm expects to spin it out in an initial public offering of shares as its revenues grew 10% for 2021 and 6% during the fourth quarter.
In its latest results on 23 February, the Laval, Quebec-based firm reported the Rx and OTC drug and dietary supplement eye health business’s revenues reached $1bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?